Pregnancy outcomes in Autoimmune rheumatic disease Associated secondary Anti phospholipid syndrome vs primary Antiphospholipid syndrome: A retrospective observational study from Quaternery centre Apollo main hospital chennai

BackgroundAntiphospholipid syndrome (APS) complicating pregnancy carries significant obstetric morbidity. Secondary APS, arising in the context of systemic autoimmune disease, may confer worse outcomes than primary APS due to additional inflammatory and immunological mechanisms. This study aimed to compare pregnancy outcomes between autoimmune rheumatic disease-associated secondary APS and primary APS managed at a quaternary care hospital in Chennai. MethodsA retrospective observational study analysed 82 pregnancies (secondary APS n=46; primary APS n=36) managed between January 2025 and March 2026. Outcomes including live birth rate, miscarriage, fetal death, preterm birth, pre-eclampsia, and intrauterine growth restriction (IUGR) were compared using chi-square test, Fisher exact test, and independent t-test. Multivariable logistic regression identified independent predictors of adverse outcomes. ResultsLive birth rate was significantly lower in secondary APS compared to primary APS (69.6% vs 86.1%; p=0.048). Triple antiphospholipid antibody positivity was more prevalent in secondary APS (47.8% vs 25.0%; p=0.032). On multivariable analysis, secondary APS (aOR 2.71; 95% CI 1.08-6.81; p=0.033), triple positivity (aOR 3.45; 95% CI 1.39-8.57; p=0.007), and lupus anticoagulant (aOR 2.62; 95% CI 1.01-6.76; p=0.047) independently predicted adverse outcomes. Hydroxychloroquine (aOR 0.39; p=0.038) and combination aspirin plus low-molecular-weight heparin (aOR 0.31; p=0.019) were independently protective. ConclusionSecondary APS is associated with significantly worse pregnancy outcomes than primary APS. Triple antiphospholipid positivity and lupus anticoagulant independently increase obstetric risk. Hydroxychloroquine and combination antithrombotic therapy significantly improve live birth rates. Early rheumatology referral and multidisciplinary obstetric management are essential.